Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solution
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia, Near Vision, Miosis, Eye Diseases
Trial Timeline
Sep 27, 2023 → Jan 27, 2025
NCT ID
NCT06045299About Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solution
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solution is a phase 3 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT06045299. Target conditions include Presbyopia, Near Vision, Miosis.
What happened to similar drugs?
1 of 5 similar drugs in Presbyopia were approved
Approved (1) Terminated (1) Active (4)
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06045299 | Phase 3 | Completed |
Competing Products
14 competing products in Presbyopia